BioSpace News Archive

Deals

Vertex Branches Into Diabetes, Acquiring Semma for $950 Million

Semma will become a separate operating subsidiary of Vertex. Semma is working to advance Melton’s methodology for creating billions of functional, insulin-producing beta cells.

September 3, 2019
·
3 min read
·
Mark Terry
Drug Development

Novartis’ Entresto Produces Mixed Results in Two Clinical Trials

The trials were the PROVE-HF and EVALUATE-HF trials.

September 3, 2019
·
3 min read
·
Mark Terry
Employer Resources

How Ghosting Can Shatter Your Business’ Reputation

Practicing “ghosting” can easily demolish your business’ reputation and break down relationships between both potential clients and employees.

September 3, 2019
·
4 min read
·
Kymberlie Krieger
Job Trends

Denver Health, Alongside Harm Reduction Action Center, to Recognize Overdose Awareness Day with Community Partners and Mayor in Effort to Reduce Stigma and Educate Public

Overdose Awareness Day – Participants will march from Harm Reduction Action Center to the Rita Bass EMS Education building on the Denver Health campus in observance of International Overdose Awareness Day.

September 3, 2019
·
2 min read
Business

Mario Polywka Joins Orbit Discovery’s Board of Directors

Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director.

September 3, 2019
·
2 min read
Drug Development

AstraZeneca’s Great Weekend—Positive Results in Two Trials

AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.

September 3, 2019
·
3 min read
·
Mark Terry
Policy

Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

September 3, 2019
·
5 min read
Drug Development

Genentech’s Xofluza Reduces Flu Threat by 86% Following Exposure, Data Shows

Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.

September 3, 2019
·
2 min read
·
Alex Keown
Biotech Bay

Ultragenyx to Present at Upcoming September 2019 Investor Conferences

Ultragenyx Pharmaceutical Inc. announced that Shalini Sharp, the company’s Chief Financial Officer, will present at the following conferences

September 3, 2019
·
1 min read
Deals

MGB Biopharma Announces Completion of Funding Round

MGB Biopharma announces the completion of its latest funding round.

September 3, 2019
·
5 min read